elaxine sr 37.5 venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
arrotex pharmaceuticals pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - elaxine sr 37.5 is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
alembic venlafaxine xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - alembic venlafaxine xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine medis xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
medis pharma pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: iron oxide black; ethylcellulose; colloidal anhydrous silica; copovidone; titanium dioxide; magnesium stearate; povidone; gelatin; microcrystalline cellulose; purified talc; iron oxide red; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine medis xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine appl xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine appl xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine apl xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine apl xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine apgh xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine apgh xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine apel xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine apel xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine apal xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine apal xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine alsa xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine alsa xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.
venlafaxine alma xr venlafaxine (as hydrochloride) 37.5 mg modified release capsule blister pack
alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 42.45 mg (equivalent: venlafaxine, qty 37.5 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; copovidone; gelatin; magnesium stearate; titanium dioxide; povidone; iron oxide black; iron oxide yellow; colloidal anhydrous silica; purified talc; iron oxide red; ethylcellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia - venlafaxine alma xr is indicated for the treatment of: - major depression, including prevention of relapse and recurrence where appropriate; - generalised anxiety disorder; - social anxiety disorder; panic disorder, including prevention of relapse.